3.88
-0.04 (-1.02%)
| Previous Close | 3.92 |
| Open | 3.94 |
| Volume | 1,042,077 |
| Avg. Volume (3M) | 1,051,870 |
| Market Cap | 576,438,400 |
| Price / Earnings (TTM) | 12.13 |
| Price / Earnings (Forward) | 19.53 |
| Price / Sales | 1.39 |
| Price / Book | 2.22 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | 11.40% |
| Operating Margin (TTM) | 9.35% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 4.10% |
| Quarterly Earnings Growth (YOY) | -24.20% |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 4.70 |
| Operating Cash Flow (TTM) | 65.52 M |
| Levered Free Cash Flow (TTM) | 53.10 M |
| Return on Assets (TTM) | 13.80% |
| Return on Equity (TTM) | 22.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | MiMedx Group, Inc | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.90 |
|
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.71% |
| % Held by Institutions | 70.12% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BIERMAN JAMES L | 3.64 | - | 50,913 | 185,323 |
| HAWKINS WILLIAM A | 3.64 | - | 50,913 | 185,323 |
| NEWTON TODD | 3.64 | - | 50,913 | 185,323 |
| OLSON TIFFANY | 3.64 | - | 50,913 | 185,323 |
| PUHY DOROTHY E | 3.64 | - | 50,913 | 185,323 |
| Aggregate Net Quantity | 254,565 | |||
| Aggregate Net Value ($) | 926,617 | |||
| Aggregate Avg. Buy ($) | 3.64 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| OLSON TIFFANY | Director | 10 Jun 2026 | Acquired (+) | 50,913 | 3.64 | 185,323 |
| HAWKINS WILLIAM A | Director | 10 Jun 2026 | Acquired (+) | 50,913 | 3.64 | 185,323 |
| NEWTON TODD | Director | 10 Jun 2026 | Acquired (+) | 50,913 | 3.64 | 185,323 |
| PUHY DOROTHY E | Director | 10 Jun 2026 | Acquired (+) | 50,913 | 3.64 | 185,323 |
| BIERMAN JAMES L | Director | 10 Jun 2026 | Acquired (+) | 50,913 | 3.64 | 185,323 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |